Shares of Senseonics Holdings, Inc. (NASDAQ:SENS) have been given an average broker rating score of 2.60 (Hold) from the five analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. Senseonics’ rating score has declined by 18.2% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a 12-month consensus price objective of $4.18 for the company and are expecting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given Senseonics an industry rank of 91 out of 255 based on the ratings given to its competitors.
Shares of Senseonics stock traded down $0.07 during trading hours on Friday, hitting $1.95. The company had a trading volume of 1,878,765 shares, compared to its average volume of 1,790,108. Senseonics has a twelve month low of $1.93 and a twelve month high of $5.29.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Recommended Story: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.